Trial Profile
Comparative Assessment of Tolerability, Efficacy and Safety of Combination of Compound CDRI 80/574 and Atorvastatin versus Atorvastatin in subjects with Hyperlipidemia (A Randomized, Double-blind, Parallel-group, Active-comparator Controlled, Phase II Clinical Study).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary) ; Centatin (Primary)
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- Sponsors Cadila Pharmaceuticals
- 29 Sep 2011 New trial record